Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | CCR3 | P51677 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21644390 | 1.00 | NR1H2 (0.35) | NR1H2NR1H3ALDH1A1ACHECHRM4 | |
| SCHEMBL21644312 | 0.93 | ACHE (0.38) | NR1H2NR1H3ACHECHRM4KDM4E | |
| SCHEMBL21644310 | 0.93 | ACHE (0.38) | NR1H2NR1H3ACHECHRM4KDM4E | |
| SCHEMBL20071819 | 0.93 | SCN9A (0.35) | NR1H2NR1H3ALDH1A1ACHECHRM4 | |
| SCHEMBL21644276 | 0.93 | SCN9A (0.35) | NR1H2NR1H3ALDH1A1ACHECHRM4 | |
| SCHEMBL21644306 | 0.93 | NR1H2 (0.39) | NR1H2NR1H3ALDH1A1ACHECHRM4 | |
| SCHEMBL21644153 | 0.93 | NR1H2 (0.39) | NR1H2NR1H3ALDH1A1ACHECHRM4 | |
| SCHEMBL21644198 | 0.93 | ACHE (0.34) | NR1H2NR1H3ALDH1A1ACHECHRM4 | |
| SCHEMBL20071829 | 0.93 | ACHE (0.34) | NR1H2NR1H3ALDH1A1ACHECHRM4 | |
| SCHEMBL20072012 | 0.93 | NR1H2 (0.39) | NR1H2NR1H3ALDH1A1ACHECHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526203-B1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3526203-B1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2021-09-22 | — | — | EP | disclosed |
| US-10961215-B2 | N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10961215-B2 | N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200039951-A1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20200039951-A1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2020-02-06 | — | — | US | disclosed |
| WO-2018071313-A1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039951-A1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885ALDH1A1 736/4885 |
| US-10961215-B2 | N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885ALDH1A1 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.